Advertisement

Topics

AACR: Busy start for Bristol-Myers Squibb's Opdivo

08:15 EDT 3 Apr 2017 | BioPharmaDive

New data from two abstracts presented at the research conference gave a clearer picture of Opdivo's long-term survival benefit. 

Original Article: AACR: Busy start for Bristol-Myers Squibb's Opdivo

NEXT ARTICLE

More From BioPortfolio on "AACR: Busy start for Bristol-Myers Squibb's Opdivo"

Quick Search
Advertisement